BioSpace News Archive

Sierra Oncology, Inc., a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, announced the company will participate in the 2021 Jefferies London Healthcare Conference.

MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces that its Chief Executive Officer, Robert Habib, will present and host one-on-one meetings at the Jefferies 2021 London Healthcare Conference, taking place from 16-19 November 2021 in-person and virtually.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced the Company’s CEO Dr. Pnina Fishman will present at the H.C. Wainwright 7th Annual Israel Conference on Monday, November 15, 2021 at 12:30 PM ET.

Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented new data from its best-in-class memory natural killer (NK) cell therapy platform at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting.

MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces positive safety data from the Phase 1a/b TIMEPOINT study of MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours.

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented new SQZ™ AAC and eAPC preclinical research describing the robust potential of these platforms to treat cancer, including data demonstrating synergistic activity when combined with chemotherapy.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), today announced final Phase 1b data for EDP-514, a novel pangenotypic class II hepatitis B virus (HBV) core inhibitor, in conjunction with two posters presented at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD).

LENSAR, Inc. today announced that two posters have been accepted for virtual presentation at the Annual Meeting of the American Academy of Ophthalmology (AAO)

PureTech Presents Clinical Trial Design Supporting Wholly Owned Immuno-Oncology Candidate LYT-200 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Xencor Presents Data from Multiple Preclinical XmAb ® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting